Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

DURECT Corporation (DRRX)

-NasdaqGM
1.31 Up 0.02(1.55%) Apr 17, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
DURECT Corporation
10260 Bubb Road
Cupertino, CA 95014
United States - Map
Phone: 408-777-1417
Fax: 408-777-3577
Website: http://www.durect.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:101

Business Summary 

DURECT Corporation, a specialty pharmaceutical company, is engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms in the United States and internationally. It focuses on the development of various products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, metabolic disorders, cardiovascular disease, and other chronic diseases. The company’s products comprise ALZET product line that consists of osmotic pumps and accessories, which are used for experimental research in mice, rats, and other laboratory animals; and a range of standard and custom biodegradable polymers that are used as raw materials in the pharmaceutical and medical devices under the brand name of LACTEL. Its products also include REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain that has completed Phase III clinical study; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR-Sufentanil that has completed Phase II transdermal sufentanil patch, which is intended to provide delivery of sufentanil. In addition, the company’s products pipeline comprises ORADUR-based opioids, including hydrocodone and hydromorphone that are in Phase I clinical trials for the treatment of pain; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It has strategic agreements with various companies, such as Pain Therapeutics, Inc.; Pfizer Inc.; Zogenix, Inc.; Hospira, Inc.; and Nycomed Danmark ApS. The company was founded in 1998 and is headquartered in Cupertino, California.

Key Statistics


Company Websites 
Home Page
Investor Relations
Search Yahoo! for:
More on DURECT Corporation

Key Executives 
 PayExercised
Dr. Felix Theeuwes D.Sc., Ph.D., 76
Co-Founder, Chairman and Chief Scientific Officer
284.00K0.00
Dr. James E. Brown D.V.M., 57
Co-Founder, Chief Exec. Officer, Pres and Director
477.00K0.00
Mr. Matthew J. Hogan M.B.A, 54
Chief Financial Officer, Principal Accounting Officer and Sec.
324.00K0.00
Dr. Su Il Yum Ph.D., 75
Exec. VP of Pharmaceutical Systems R&D
309.00K62.00K
Ms. Judy Joice ,
Sr. VP of Operations and Corp. Quality Assurance
N/AN/A
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders